2025 Annual Meeting | Industry Therapeutic Update from Novartis Pharmaceuticals: Understanding BTK Signaling in Neurology: Exploring This Pathway in Neuroinflammation

��ɫ��

2025 Annual Meeting | Industry Therapeutic Update from Novartis Pharmaceuticals: Understanding BTK Signaling in Neurology: Exploring This Pathway in Neuroinflammation

Date Tuesday 04/08/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Bruno Cenni, PhD

Topic(s) General Neurology, Cerebrovascular Disease and Interventional Neurology, Multiple Sclerosis

Learning Objectives This program will explore the role of the Bruton’s tyrosine kinase (BTK) enzyme in the pathogenesis of neuroinflammation. This session will provide a comprehensive review of the underlying pathways of BTK in immune signaling and their role in neuroinflammation.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Therapeutic Update from Novartis Pharmaceuticals: Understanding BTK Signaling in Neurology: Exploring This Pathway in Neuroinflammation

Faculty Disclosures
Bruno Cenni, PhD	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��